Nanohale AG (ETR:FYB) | WebDisclosure

Basculer en Français

9480	Companies
185562	Keywords
117961	Articles
99395	Press releases

Home
Companies
Nanohale AG

PRESS RELEASE

published on 10/01/2024 at 17:06, 1 year 2 months ago

Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research GmbH releases an update on Formycon AG, with analyst Simon Scholes reiterating a BUY rating and raising the price target from EUR 80 to EUR 82. The approval of the biosimilar FYB202 in the EU and US contributes to the positive outlook on Formycon's market share prospects

Investment Recommendation Formycon AG First Berlin Equity Research GmbH FYB202 Approval Biosimilar Market
BRIEF

published on 09/30/2024 at 07:35, 1 year 2 months ago

Formycon and Fresenius Kabi Receive FDA Approval for Biosimilar Otulfi

FDA Approval Biosimilar Formycon Fresenius Kabi Otulfi
BRIEF

published on 09/30/2024 at 07:35, 1 year 2 months ago

Formycon et Fresenius Kabi reçoivent l'approbation de la FDA pour le biosimilaire Otulfi

Approbation De La FDA Formycon Fresenius Kabi Biosimilaire Otulfi
PRESS RELEASE

published on 09/30/2024 at 07:30, 1 year 2 months ago

Formycon and Fresenius Kabi receive FDA approval for FYB202/ OtulfiTM (ustekinumab-aauz)
Formycon and Fresenius Kabi receive FDA approval for FYB202/OtulfiTM (ustekinumab-aauz) to treat several conditions including Crohn’s disease and psoriasis, expanding biosimilar market presence

FDA Approval Biosimilar Formycon Fresenius Kabi Ustekinumab
BRIEF

published on 09/27/2024 at 22:01, 1 year 2 months ago

FDA Grants Approval for Stelara® Biosimilar FYB202/OtulfiTM

FDA Approval Pharmaceutical Formycon AG Biosimilar Stelara®
BRIEF

published on 09/27/2024 at 22:01, 1 year 2 months ago

La FDA approuve le biosimilaire Stelara® FYB202/OtulfiTM

Formycon AG Approbation De La FDA Pharmaceutique Biosimilaire Stelara®
PRESS RELEASE

published on 09/27/2024 at 21:56, 1 year 2 months ago

EQS-Adhoc: FDA grants approval for Stelara® Biosimilar FYB202/OtulfiTM (ustekinumab-aauz)
FDA grants approval for Stelara Biosimilar FYB202/Otulfi (ustekinumab-aauz) by Formycon AG. Approval based on comprehensive data evaluation. Contact: Sabrina Mueller, Formycon AG

FDA Approval Formycon AG FYB202 Stelara Biosimilar Sabrina Mueller
BRIEF

published on 09/27/2024 at 09:05, 1 year 2 months ago

European Commission Approves Formycon and Fresenius Kabi's Biosimilar FYB202/Otulfi®

European Commission Formycon Fresenius Kabi FYB202 Ustekinumab
BRIEF

published on 09/27/2024 at 09:05, 1 year 2 months ago

La Commission européenne approuve le biosimilaire FYB202/Otulfi® de Formycon et Fresenius Kabi

Formycon Fresenius Kabi FYB202 Ustekinumab Commission Européenne
PRESS RELEASE

published on 09/27/2024 at 09:00, 1 year 2 months ago

Formycon and Fresenius Kabi receive European Commission approval for FYB202/Otulfi® (ustekinumab) for the treatment of serious inflammatory diseases
Formycon and Fresenius Kabi secure European Commission approval for FYB202/Otulfi® (ustekinumab) to treat inflammatory diseases, expanding biosimilar portfolio

Biosimilar Formycon Fresenius Kabi Ustekinumab European Commission Approval

Accesswire

Published on 12/05/2025 at 22:50, 32 minutes ago

Banyan Gold Grants Incentive Stock Options
Published on 12/05/2025 at 21:45, 1 hour 37 minutes ago

When the Architecture Becomes Visible: The SMX Revaluation Explained
Published on 12/05/2025 at 21:30, 1 hour 52 minutes ago

The Identity Layer Beneath Everything: Why Markets Are Revaluing SMX All at Once
Published on 12/05/2025 at 21:20, 2 hours 2 minutes ago

Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement
Published on 12/05/2025 at 21:00, 2 hours 22 minutes ago

The Repricing Event: Why Multiple Global Industries Are Suddenly Moving Toward SMX

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 22:15, 1 hour 6 minutes ago

CPI PROPERTY GROUP - Changes in Shareholding and Board of Directors
Published on 12/05/2025 at 22:12, 1 hour 10 minutes ago

EQS-Adhoc: CPI PROPERTY GROUP - Change to Distribution Policy
Published on 12/05/2025 at 18:58, 4 hours 24 minutes ago

EQS-Adhoc: HORNBACH Holding AG & Co. KGaA: Reduced earnings in Q3 2025/26 – Guidance for adjusted EBIT at previous year’s level still valid
Published on 12/05/2025 at 18:26, 4 hours 55 minutes ago

POS-Transaction in Own Shares
Published on 12/05/2025 at 18:15, 5 hours 7 minutes ago

Completion of merger to form Helvetia Baloise Holding Ltd

Les Echos

Published on 12/05/2025 at 23:00, 22 minutes ago

ALTAREIT : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 12/05/2025 at 23:00, 22 minutes ago

ALTAREA : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 12/05/2025 at 23:00, 22 minutes ago

ALTAREA : DÉCLARATION MENSUELLE DES OPÉRATIONS RÉALISÉES PAR LA SOCIÉTÉ SUR SES PROPRES TITRES NOVEMBRE 2025
Published on 12/05/2025 at 23:00, 22 minutes ago

ALTAREIT : DÉCLARATION MENSUELLE DES OPÉRATIONS RÉALISÉES PAR LA SOCIÉTÉ SUR SES PROPRES TITRES NOVEMBRE 2025
Published on 12/05/2025 at 17:18, 6 hours 4 minutes ago

La vidéo de la réunion de présentation des résultats 2024-2025 du 5 décembre 2025 est disponible

View all LES ECHOS COMFI WIRE